# Amgen Inc. (AMGN)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $191.90B  
**Price:** $354.06 (+4.84%)

> Amgen Inc. is a biotechnology company that discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on innovative medicines addressing serious illnesses in areas such as oncology, inflammation, cardiovascular disease, bone health, nephrology, and neurology. Key products target conditions like cancer, rheumatoid arthritis, osteoporosis, anemia, and migraines, providing treatments that help manage chronic diseases and improve patient outcomes. Amgen Inc. serves healthcare providers including physicians, clinics, dialysis centers, hospitals, and pharmacies, distributing its portfolio through pharmaceutical wholesale distributors. The company also engages in collaborations, such as partnerships for development and commercialization of specific therapies. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen Inc. plays a vital role in the biotechnology sector by advancing biologic medicines that address unmet medical needs and contribute to global healthcare advancements.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $36.75B | $24.71B | $9.08B | $7.71B | $14.23 |
| 2024 | $33.42B | $20.57B | $7.26B | $4.09B | $7.56 |
| 2023 | $28.19B | $19.74B | $7.90B | $6.72B | $12.49 |
| 2022 | $26.32B | $19.92B | $9.57B | $6.55B | $12.11 |
| 2021 | $25.98B | $19.52B | $7.64B | $5.89B | $10.28 |
| 2020 | $25.42B | $19.27B | $9.14B | $7.26B | $12.31 |
| 2019 | $23.36B | $19.01B | $9.67B | $7.84B | $12.88 |
| 2018 | $23.75B | $19.65B | $10.26B | $8.39B | $12.62 |
| 2017 | $22.85B | $18.78B | $9.97B | $1.98B | $2.69 |
| 2016 | $22.99B | $18.83B | $9.79B | $7.72B | $10.24 |
| 2015 | $21.66B | $17.43B | $8.47B | $6.94B | $9.06 |
| 2014 | $20.06B | $15.64B | $6.19B | $5.16B | $6.70 |
| 2013 | $18.68B | $15.33B | $5.87B | $5.08B | $6.64 |
| 2012 | $17.27B | $14.07B | $5.58B | $4.34B | $5.52 |
| 2011 | $15.58B | $12.87B | $4.31B | $3.68B | $4.04 |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $90.59B | $81.93B | $8.66B | $9.13B | $54.60B |
| 2024 | $91.84B | $85.96B | $5.88B | $11.97B | $60.10B |
| 2023 | $97.15B | $90.92B | $6.23B | $10.94B | $64.61B |
| 2022 | $65.12B | $61.46B | $3.66B | $7.63B | $38.95B |
| 2021 | $61.16B | $54.47B | $6.70B | $7.99B | $33.31B |
| 2020 | $62.95B | $53.54B | $9.41B | $6.27B | $32.99B |
| 2019 | $59.71B | $50.03B | $9.67B | $6.04B | $29.90B |
| 2018 | $66.42B | $53.92B | $12.50B | $6.95B | $33.93B |
| 2017 | $79.95B | $54.71B | $25.24B | $3.80B | $35.34B |
| 2016 | $77.63B | $47.75B | $29.88B | $3.24B | $34.60B |
| 2015 | $71.45B | $43.37B | $28.08B | $4.14B | $31.43B |
| 2014 | $69.01B | $43.23B | $25.78B | $3.73B | $30.71B |
| 2013 | $66.13B | $44.03B | $22.10B | $3.81B | $32.13B |
| 2012 | $54.30B | $35.24B | $19.06B | $3.26B | $26.53B |
| 2011 | $48.87B | $29.84B | $19.03B | $6.95B | $21.43B |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | $9.96B | $1.86B | $8.10B |
| 2024 | $11.49B | $1.10B | $10.39B |
| 2023 | $8.47B | $1.11B | $7.36B |
| 2022 | $9.72B | $936M | $8.79B |
| 2021 | $9.26B | $880M | $8.38B |
| 2020 | $10.50B | $608M | $9.89B |
| 2019 | $9.15B | $618M | $8.53B |
| 2018 | $11.30B | $738M | $10.56B |
| 2017 | $11.18B | $664M | $10.51B |
| 2016 | $10.35B | $738M | $9.62B |
| 2015 | $9.73B | $594M | $9.14B |
| 2014 | $8.95B | $718M | $8.23B |
| 2013 | $6.29B | $693M | $5.60B |
| 2012 | $5.88B | $689M | $5.19B |
| 2011 | $5.12B | $567M | $4.55B |

Source: [CompaniesByCap](https://companiesbycap.com/company/AMGN)